Home/Filings/4/0001209191-16-153091
4//SEC Filing

Orexigen Therapeutics, Inc. 4

Accession 0001209191-16-153091

CIK 0001382911operating

Filed

Dec 1, 7:00 PM ET

Accepted

Dec 2, 5:09 PM ET

Size

8.0 KB

Accession

0001209191-16-153091

Insider Transaction Report

Form 4
Period: 2016-11-30
Cannell Thomas R
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2016-11-30$1.67/sh+291$4861,763 total
Footnotes (1)
  • [F1]Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.

Issuer

Orexigen Therapeutics, Inc.

CIK 0001382911

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001382911

Filing Metadata

Form type
4
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 5:09 PM ET
Size
8.0 KB